--- title: "Sodexo Expands Adventist Health Partnership With $70 Million Contract Covering 15 New Sites" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273398493.md" datetime: "2026-01-22T16:03:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273398493.md) - [en](https://longbridge.com/en/news/273398493.md) - [zh-HK](https://longbridge.com/zh-HK/news/273398493.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273398493.md) | [繁體中文](https://longbridge.com/zh-HK/news/273398493.md) # Sodexo Expands Adventist Health Partnership With $70 Million Contract Covering 15 New Sites Sodexo SA has announced the expansion of its partnership with Adventist Health through a new multi-year contract covering 15 additional sites in California, Hawaii, and Oregon. This brings the total number of Adventist Health sites managed by Sodexo to 26. The contract, valued at approximately $70 million, will take effect on January 1, 2026, and includes the recruitment of over 400 new employees. Sodexo will provide services focused on hygiene, patient comfort, operational efficiency, and care standards, along with technology solutions such as UVD robots, E-daily assignments, dynamic cleaning, and its proprietary Experiencia® platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sodexo SA published the original content used to generate this news brief on January 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here ### 相关股票 - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md) - [Proshares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/zh-CN/quote/BIS.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) ## 相关资讯与研究 - [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/zh-CN/news/281544776.md) - [Cloudbreak Pharma's 2025 Loss Narrows](https://longbridge.com/zh-CN/news/281317115.md) - [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-CN/news/281644038.md) - [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-CN/news/281346305.md) - [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/zh-CN/news/281174396.md)